Phase I study of orally administered 14 Carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase inhibitor, to assess the absorption, metabolism, excretion, and pharmacokinetics in patients with advanced solid malignancies

• Published in: Cancer chemotherapy and pharmacology Vol. 83; no. 4; p. 787
• Main Authors: MacDonald, Alexander, Scarfe, Graeme, Magirr, Dominic, Sarvotham, Tinnu, Charlton, Julie, Brugger, Wolfram, Dean, Emma
• Format: Journal Article
• Language: English
• Published: Germany 01.04.2019
• Subjects: Administration, Oral; Aged; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacokinetics; Area Under Curve; Benzamides - administration & dosage; Benzamides - pharmacokinetics; Carbon Radioisotopes; Female; Humans; Male; Mechanistic Target of Rapamycin Complex 1 - antagonists & inhibitors; Mechanistic Target of Rapamycin Complex 2 - antagonists & inhibitors; Middle Aged; Morpholines - administration & dosage; Morpholines - pharmacokinetics; Neoplasms - drug therapy; Neoplasms - pathology; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - pharmacokinetics; Pyrimidines - administration & dosage; Pyrimidines - pharmacokinetics; AZD2014; Phase I; ADME; Vistusertib; Metabolism; Solid malignancies

Vistusertib is an orally bioavailable dual target of rapamycin complex (TORC) 1/2 kinase inhibitor currently under clinical investigation in various solid tumour and haematological malignancy settings. The pharmacokinetic, metabolic and excretion profiles of Carbon-isotope ( C)-labelled vistusertib...